2012 was a busy year with lots of developments in biosimilars from regulatory guidelines to comparability issues.  Biosimilars remain as the hot topic of the year for GaBI Online.

So what were the most viewed stories in GaBI Online 2012? To ensure that none of GaBI Online’s readers missed out on what happened in 2012, below is a list of the top 10 most read articles in 2012. Follow the links in the titles of each article to find out more… 

From this ‘most read’ articles overview, the issue on biosimilar comparability (1st and 9th position) attracts a lot of interest and requires further input from experts. For this subject, GaBI Journal introduced a Special Issue on ‘Biosimilarity and Interchangeability’ with Professor Shein-Chung Chow as the Guest Editor.

Check out the first article titled ‘Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act’ by Professor Chow published in GaBI Journal, online first.

Biosimilar terminology (3rd position) requires proper clarification and definition. For this topic GaBI Journal publishes a full paper by Dr Robin Thorpe.

Another topic of interest is the European uptake of biosimilars (2nd position). Biosimilars entered the EU market in 2008 and uptake has been slow. What are the barriers affecting the uptake? How to resolve this? GaBI will cover this topic in 2013 via the educational series on ‘Biosimilars for healthcare professionals’. Click here to find out more.

If you are interested in contributing a research article in an area of interest to GaBI Journal, please send us your submission here.

GaBI’s mission – Building trust in cost-effective treatments

Editor’s comment
What do you think about GaBI Online providing overviews of this type? Please feel free to share your thoughts via email or in the comments section below. What other overviews would you like to see?

Related article

Top 10 most read GaBI Online articles in 2011

Source: www.gabionline.net